Waldenström's Macroglobulinemia Veronique Leblond
Publisher: Springer International Publishing
Waldenström's macroglobulinemia: clinical features, complications, and management. Woojin Kim, M.D., and Euiyong Kweon, M.D., Ph.D. Treatment recommendations for patients with Waldenström macroglobulinemia ( WM) and related disorders: IWWM-7 consensus. What happens after treatment for Waldenstrom macroglobulinemia? Anemia represents a reduction in the oxygen-carrying capacity of the blood. This is Cancer.Net's Guide to Waldenstrom's Macroglobulinemia. Waldenström's macroglobulinemia is a low-grade lymphoplasmacytic lymphoma. In some cases, people can have Waldenström's macroglobulinemia for years without showing any symptoms. Waldenström's macroglobulinemia is a type of non-Hodgkin lymphoma. FS20 Waldenström Macroglobulinemia Facts I page 1. Waldenström's macroglobulinemia is an incurable, IgM-secreting lymphoplasmacytic lymphoma (LPL). Waldenström macroglobulinemia, one of the malignant monoclonal gammopathies, is a chronic, indolent, lymphoproliferative disorder. Requiring treatment of Waldenström macroglobulinemia. Source: Participating patient organizations visible below. Hyperviscosity-Related Retinopathy in Waldenström's Macroglobulinemia. Use the menu below to choose the Overview section to get started. Novel agents in the treatment of Waldenström's macroglobulinemia. Waldenström macroglobulinemia (WM) is a rare form of blood cancer. If signs or symptoms suggest that a person may have Waldenstrommacroglobulinemia (WM), more exams and tests will be done. It has an overall incidence of 2.5/million/year.